Earlier Steroid Use Does Not Decrease the Severity or Duration of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Large B-Cell Lymphoma (LBCL) Who Received Axicabtagene Ciloleucel (axi-cel).

Samuel Weeks,Myla Strawderman,Kara Kubli,Joseph Ditursi,Patrick M Reagan

doi:10.1016/j.jtct.2023.12.247

Earlier Steroid Use Does Not Decrease the Severity or Duration of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Large B-Cell Lymphoma (LBCL) Who Received Axicabtagene Ciloleucel (axi-cel).

Samuel Weeks, Myla Strawderman + Show 3 more

https://doi.org/10.1016/j.jtct.2023.12.247

Copy DOI

Journal: Biology of Blood and Marrow Transplantation

Publication Date: Feb 1, 2024

#Immune Effector Cell-Associated Neurotoxicity Syndrome #Cytokine Release Syndrome + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Earlier Steroid Use Does Not Decrease the Severity or Duration of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Large B-Cell Lymphoma (LBCL) Who Received Axicabtagene Ciloleucel (axi-cel).

Full Text